Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of NX-5948 in relapsed/refractory B-cell malignancies
NL-OMON54003Phase 1Recruiting
- Sponsor
- Nurix Therapeutics
- Start
- Oct 2023
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bexobrutideg in B-cell malignancy, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL) and 7 more (3 arms), sponsored by Nurix Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events, Changes from baseline in safety parameters and 2 more. Started Oct 2023; status: recruiting.
02
Drugs
bexobrutideg
03
Conditions
B-cell malignancychronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON54003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54003.